TN2011000454A1 - Derives de benzofurannyle utilises comme inhibiteurs de glucokinase - Google Patents

Derives de benzofurannyle utilises comme inhibiteurs de glucokinase

Info

Publication number
TN2011000454A1
TN2011000454A1 TN2011000454A TN2011000454A TN2011000454A1 TN 2011000454 A1 TN2011000454 A1 TN 2011000454A1 TN 2011000454 A TN2011000454 A TN 2011000454A TN 2011000454 A TN2011000454 A TN 2011000454A TN 2011000454 A1 TN2011000454 A1 TN 2011000454A1
Authority
TN
Tunisia
Prior art keywords
glucokinase
benzofurannyl
derivatives
des
glucokinase inhibitors
Prior art date
Application number
TN2011000454A
Other languages
English (en)
Inventor
Anthony Lai Ling
Jeffrey Allen Pfefferkorn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42124287&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000454(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TN2011000454A1 publication Critical patent/TN2011000454A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La présente invention propose des composés de formule (I) qui jouent le role d'activateurs de glucokinase; des compositions pharmaceutiques les contenant et des procédés pour le traitement de maladies, de troubles, ou d'affections à médiation par la glucokinase.
TN2011000454A 2009-03-11 2011-09-08 Derives de benzofurannyle utilises comme inhibiteurs de glucokinase TN2011000454A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15909909P 2009-03-11 2009-03-11
PCT/IB2010/050943 WO2010103437A1 (fr) 2009-03-11 2010-03-04 Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase

Publications (1)

Publication Number Publication Date
TN2011000454A1 true TN2011000454A1 (fr) 2013-03-27

Family

ID=42124287

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000454A TN2011000454A1 (fr) 2009-03-11 2011-09-08 Derives de benzofurannyle utilises comme inhibiteurs de glucokinase

Country Status (38)

Country Link
US (2) US8455496B2 (fr)
EP (2) EP2406253B1 (fr)
JP (1) JP5086480B2 (fr)
KR (1) KR101295937B1 (fr)
CN (1) CN102388038B (fr)
AP (1) AP3179A (fr)
AR (1) AR075729A1 (fr)
AU (1) AU2010222589B2 (fr)
BR (1) BRPI1013246B1 (fr)
CA (1) CA2754681C (fr)
CL (1) CL2011002185A1 (fr)
CO (1) CO6430427A2 (fr)
CR (1) CR20110467A (fr)
CU (1) CU24036B1 (fr)
DK (1) DK2406253T3 (fr)
DO (1) DOP2011000279A (fr)
EA (1) EA018894B1 (fr)
EC (1) ECSP11011306A (fr)
ES (1) ES2427279T3 (fr)
GE (1) GEP20156239B (fr)
HK (1) HK1164281A1 (fr)
HR (1) HRP20130661T1 (fr)
IL (1) IL214942A (fr)
MA (1) MA33119B1 (fr)
MY (1) MY151246A (fr)
NI (1) NI201100166A (fr)
NZ (1) NZ595024A (fr)
PE (1) PE20120668A1 (fr)
PL (1) PL2406253T3 (fr)
PT (1) PT2406253E (fr)
RS (1) RS52903B (fr)
SI (1) SI2406253T1 (fr)
TN (1) TN2011000454A1 (fr)
TW (1) TWI383981B (fr)
UA (1) UA99882C2 (fr)
UY (1) UY32480A (fr)
WO (1) WO2010103437A1 (fr)
ZA (1) ZA201106632B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025774T2 (en) 2010-03-19 2016-05-30 Pfizer 2,3-Dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
RU2540337C2 (ru) 2010-10-29 2015-02-10 Пфайзер Инк. N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
PL2699576T3 (pl) 2011-04-22 2016-05-31 Pfizer Pochodne pirazolospiroketonu do zastosowania jako inhibitory karboksylazy acetylo-COA
JP2014520879A (ja) 2011-07-15 2014-08-25 ファイザー・インク Ｇｐｒ１１９調節因子
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2751116B1 (fr) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
UA108713C2 (xx) 2011-11-11 2015-05-25 2-тіопіримідинони
MA37385B1 (fr) 2012-04-06 2019-09-30 Pfizer Inc Etat De Delaware Inhibiteurs de diacylglycérol-acyltransférase 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
EP2897964A1 (fr) 2012-09-20 2015-07-29 Pfizer Inc. Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
CA2893256A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composes d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
EP2935282A1 (fr) 2012-12-19 2015-10-28 Pfizer Inc. Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués carbocycliques et hétérocycliques
EP2956458B1 (fr) 2013-02-13 2017-08-09 Pfizer Inc Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2015052610A1 (fr) 2013-10-09 2015-04-16 Pfizer Inc. Antagonistes de récepteur ep3 de prostaglandine
AP2016009407A0 (en) 2014-03-17 2016-08-31 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
SG11201608110WA (en) 2014-04-04 2016-10-28 Pfizer Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA030085B1 (ru) 2014-04-10 2018-06-29 Пфайзер Инк. 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
CN104387348A (zh) * 2014-10-27 2015-03-04 湖南华腾制药有限公司 一种苯并呋喃衍生物的制备方法
WO2016092413A1 (fr) 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
WO2016103097A1 (fr) 2014-12-22 2016-06-30 Pfizer Inc. Antagonistes de récepteur ep3 de prostaglandine
DK3265126T3 (da) 2015-03-03 2021-09-13 Saniona As Kombinationsformulering af tesofensin og metoprolol
MX2017014128A (es) 2015-05-05 2018-03-15 Pfizer 2-tiopirimidinonas.
JP2018516254A (ja) 2015-05-29 2018-06-21 ファイザー・インク バニン１酵素の阻害薬としての新規なヘテロ環化合物
EP3310784B1 (fr) 2015-06-17 2020-10-07 Pfizer Inc Composés tricycliques comme inhibiteurs de la phosphodiesterase.
WO2016203335A1 (fr) 2015-06-18 2016-12-22 Pfizer Inc. Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
BR112018002071A2 (pt) 2015-08-13 2018-09-18 Pfizer compostos heteroarílicos ou arílicos fundidos bicíclicos
KR102029124B1 (ko) 2015-08-27 2019-10-07 화이자 인코포레이티드 Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
WO2017051276A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
TN2018000198A1 (en) 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
JP2019524716A (ja) 2016-07-14 2019-09-05 ファイザー・インク バニン１酵素の阻害薬としての新規のピリミジンカルボキサミド
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
WO2019133445A1 (fr) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
MX2020012965A (es) * 2018-05-31 2021-02-16 Hua Medicine Shanghai Ltd Combinacion, composicion y preparacion de compuesto farmaceutico que comprende activador de glucocinasa e inhibidor de dpp-iv, metodo de preparacion y uso del mismo.
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
WO2020051309A2 (fr) * 2018-09-06 2020-03-12 Yale University Traitements contre des virus transmis par les moustiques à base de protéines issues des glandes salivaires de moustique
WO2020102575A1 (fr) 2018-11-16 2020-05-22 Inception Ibd, Inc. Aminothiazoles hétérocycliques et leurs utilisations
CA3140972A1 (fr) 2019-05-20 2020-11-26 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinees a etre utilisees dans le traitement de la nash/nafld et de maladies associees
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2020261144A1 (fr) 2019-06-28 2020-12-30 Pfizer Inc. Dérivés de 5-(thiophén-2-yl) -1h-tétrazole utilisés en tant qu'inhibiteurs de bckdk utiles pour le traitement de diverses maladies
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CR20220632A (es) 2020-06-09 2023-01-23 Pfizer Antagonistas del receptor de melanocortina 4 y usos de estos
WO2023026180A1 (fr) 2021-08-26 2023-03-02 Pfizer Inc. Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide
WO2023100061A1 (fr) 2021-12-01 2023-06-08 Pfizer Inc. Dérivés d'acide 3-phényl-1-benzothiophène-2-carboxylique utilisés en tant qu'inhibiteurs de kinase alpha-céto-acide à chaîne ramifiée pour le traitement du diabète, de maladies rénales, de la shna et de l'insuffisance cardiaque
WO2023105387A1 (fr) 2021-12-06 2023-06-15 Pfizer Inc. Antagonistes du récepteur 4 de la mélanocortine et leurs utilisations
WO2023169456A1 (fr) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Agonistes hétérocycliques de glp-1
WO2023198140A1 (fr) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
WO2024075051A1 (fr) 2022-10-07 2024-04-11 Pfizer Inc. Inhibiteurs et/ou agents de dégradation de hsd17b13

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795984A (en) * 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
AU662997B2 (en) 1992-07-03 1995-09-21 Ihara Chemical Industry Co. Ltd. Condensed heterocyclic derivative and weedkiller
US6121274A (en) * 1994-07-22 2000-09-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurane
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
KR100232341B1 (ko) * 1994-10-13 2000-07-01 디. 제이. 우드 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물
MX9702734A (es) * 1994-10-13 1997-06-28 Pfizer Benzopirano y compuestos benzocondensados, su preparacion y su uso como antagonistas de leucotrieno b4 (ltb4).
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
TR199802386T2 (xx) * 1996-05-20 1999-02-22 Darwin Discovery Limited Benzofuran karboksamidler ve bunlar�n terap�tik kullan�m�.
WO1998007715A1 (fr) * 1996-08-19 1998-02-26 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux benzofuran-4-carboxamides
CN1290266A (zh) * 1998-02-09 2001-04-04 达尔文发现有限公司 苯并呋喃－4－甲酰胺和其治疗用途
ES2339738T3 (es) * 1999-01-22 2010-05-25 Elan Pharmaceuticals, Inc. Derivados de acilo los cuales tratan trastornos relacionados con vla-4.
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2002020463A2 (fr) 2000-09-05 2002-03-14 Tularik Inc. Modulateurs fxr
CA2436854A1 (fr) 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Derives de pyridones utilises en tant qu'inhibiteurs ap2
KR100545431B1 (ko) 2000-12-06 2006-01-24 에프. 호프만-라 로슈 아게 축합된 이종방향족 글루코키나제 활성화제
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
DE60219295T2 (de) 2001-02-28 2008-01-03 Merck & Co., Inc. Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
EP1403255A4 (fr) * 2001-06-12 2005-04-06 Sumitomo Pharma Inhibiteurs de rho kinase
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
WO2003035621A1 (fr) 2001-10-22 2003-05-01 The Research Foundation Of State University Of New York Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees
GEP20063937B (en) 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
CN100357283C (zh) * 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
CA2484582A1 (fr) 2002-05-03 2003-11-13 Warner-Lambert Company Llc Antagonistes de bombesine
KR20050009747A (ko) 2002-06-13 2005-01-25 이 아이 듀폰 디 네모아 앤드 캄파니 피라졸카르복사미드 살충제
JP4302967B2 (ja) * 2002-11-18 2009-07-29 パイオニア株式会社 楽曲検索方法、楽曲検索装置及び楽曲検索プログラム
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (fr) 2002-12-23 2004-06-30 Jerini AG Utilisation de nitriles en tant qu'inhibiteurs de rotamase
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
AU2004220234C1 (en) * 2003-02-13 2013-01-17 Msd K.K. Novel 2-pyridinecarboxamide derivatives
CN100378094C (zh) * 2003-02-13 2008-04-02 万有制药株式会社 2-吡啶甲酰胺衍生物
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
EP1600442B1 (fr) * 2003-02-26 2018-01-17 Msd K.K. Derives d'heteroarylcarbamoylbenzene
MXPA06000538A (es) * 2003-07-15 2006-03-30 Smithkline Beecham Corp Compuestos novedosos.
EP1653944B1 (fr) * 2003-08-01 2010-11-10 Chugai Seiyaku Kabushiki Kaisha Composes heterocycliques utiles comme inhibiteurs de la malonyl-coa decarboxylase
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
CA2560689C (fr) 2004-04-02 2011-03-01 Novartis Ag Derives a base de sulfonamide et de thiazolopyridine en tant qu'activateurs de la glucokinase, utiles dans le traitement du diabete de type 2
CA2568056A1 (fr) 2004-05-25 2005-12-08 Pfizer Products Inc. Derives de tetraazabenzo[e]azulene et analogues de ceux-ci
JP4719745B2 (ja) 2004-07-29 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャンネル阻害剤
CA2578349A1 (fr) 2004-09-01 2006-03-16 Rigel Pharmaceuticals, Inc. Synthese de composes de 2,4-pyrimidinediamine
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SE0403006D0 (sv) * 2004-12-09 2004-12-09 Biovitrum Ab New compounds
JP2008524275A (ja) * 2004-12-21 2008-07-10 エフ．ホフマン−ラ ロシュ アーゲー クロマン誘導体及び５−ｈｔレセプターリガンドとしてのそれらの使用
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
CA2601983A1 (fr) 2005-04-06 2006-10-12 Astrazeneca Ab Heterocycles substitues et leur utilisation en tant qu'inhibiteurs de la chk1, de la pdk1 et de la pak
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
AU2006285834A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2009013065A (ja) * 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
US20090215801A9 (en) 2005-11-15 2009-08-27 Astrazeneca Ab, Sodertaije, Swedenastex Thereapeutics Ltd Novel 2-Aminopyrimidinone Derivatives And Their Use
WO2007104034A2 (fr) * 2006-03-08 2007-09-13 Takeda San Diego, Inc. Activateurs de la glucokinase
WO2007117995A2 (fr) 2006-03-30 2007-10-18 Takeda San Diego, Inc. Inhibiteurs de kinase
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
ES2487967T3 (es) * 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
JP2010138073A (ja) 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
US8299115B2 (en) 2007-06-08 2012-10-30 Debnath Bhuniya Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
CA2748587A1 (fr) * 2009-01-20 2010-07-29 Pfizer Inc. Pyrazinone amides substitues

Also Published As

Publication number Publication date
DK2406253T3 (da) 2013-08-12
EA201190158A1 (ru) 2012-04-30
NZ595024A (en) 2013-01-25
TW201036961A (en) 2010-10-16
EP2406253A1 (fr) 2012-01-18
MA33119B1 (fr) 2012-03-01
CA2754681C (fr) 2014-01-07
MY151246A (en) 2014-04-30
RS52903B (en) 2014-02-28
US20130252973A1 (en) 2013-09-26
AR075729A1 (es) 2011-04-20
US8455496B2 (en) 2013-06-04
CN102388038A (zh) 2012-03-21
IL214942A (en) 2015-10-29
DOP2011000279A (es) 2011-10-15
ZA201106632B (en) 2012-05-30
CA2754681A1 (fr) 2010-09-16
AU2010222589B2 (en) 2012-08-16
CL2011002185A1 (es) 2012-02-03
EP2406253B1 (fr) 2013-07-03
EP2604604A1 (fr) 2013-06-19
NI201100166A (es) 2012-01-23
BRPI1013246A2 (pt) 2016-04-05
US20100234285A1 (en) 2010-09-16
IL214942A0 (en) 2011-11-30
ECSP11011306A (es) 2011-10-31
JP2012520286A (ja) 2012-09-06
GEP20156239B (en) 2015-01-26
AU2010222589A1 (en) 2011-09-22
HK1164281A1 (en) 2012-09-21
CO6430427A2 (es) 2012-04-30
EA018894B1 (ru) 2013-11-29
HRP20130661T1 (en) 2013-08-31
PE20120668A1 (es) 2012-06-01
CU20110168A7 (es) 2012-02-15
ES2427279T3 (es) 2013-10-29
UY32480A (es) 2010-10-29
UA99882C2 (uk) 2012-10-10
BRPI1013246B1 (pt) 2019-10-01
TWI383981B (zh) 2013-02-01
AP3179A (en) 2015-03-31
CU24036B1 (es) 2014-10-30
CN102388038B (zh) 2014-04-23
AP2011005882A0 (en) 2011-10-31
WO2010103437A1 (fr) 2010-09-16
KR20110123288A (ko) 2011-11-14
US8735396B2 (en) 2014-05-27
PL2406253T3 (pl) 2013-10-31
PT2406253E (pt) 2013-09-11
JP5086480B2 (ja) 2012-11-28
KR101295937B1 (ko) 2013-08-14
SI2406253T1 (sl) 2013-09-30
CR20110467A (es) 2011-10-07

Similar Documents

Publication Publication Date Title
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA33492B1 (fr) Inhibiteurs de bace
MY148634A (en) Pyridazinone derivatives
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA31419B1 (fr) Derives de pyridine
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
TN2009000028A1 (fr) Agonistes de ep2
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
JO2686B1 (en) Vehicles
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
TN2009000033A1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EP2012780A4 (fr) 1h-benzimidazole-4-carboxamides substitués servant de puissants inhibiteurs de parp